BMJ5h
AB0502 CELLULAR AND PROTEOMIC CHANGES FOLLOWING ADMINISTRATION OF PERESOLIMAB, IN A PHASE 2A TRIAL IN RHEUMATOID ARTHRITIS
Background: Peresolimab is a humanized immunoglobulin G1 monoclonal antibody that stimulates human programmed cell death protein 1 (PD-1). Peresolimab demonstrated superiority to placebo in Disease ...
BMJ13h
AB1192 PREVALENCE, RISK FACTORS, AND OUTCOMES OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE IN CHINESE: A MULTI-CENTRED COHORT STUDY
1 Alice Ho Miu Ling Nethersole Hospital, Department of Medicine, Tai Po, Hong Kong (SAR) 2 The Prince of Wales Hospital, The Chinese University of Hong Kong, Department of Medicine and Therapeutics, ...